3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
Fulvestrant
65
Letrozole
55
Paclitaxel
54
pembrolizumab
42
Trastuzumab
42
ribociclib
39
Specimen Handling
36
palbociclib
35
Capecitabine
35
Carboplatin
34
Anastrozole
34
Tamoxifen
32
exemestane
31
abemaciclib
31
pertuzumab
29
Cyclophosphamide
27
Magnetic Resonance Spectroscopy
26
trastuzumab deruxtecan
24
Radiotherapy
22
Surveys and Questionnaires
20
Blood Specimen Collection
20
olaparib
18
Biopsy
18
Standard of Care
17
Docetaxel
17
Taxes
15
130-nm albumin-bound paclitaxel
15
eribulin
14
Methods
14
Mastectomy, Segmental
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled